Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus
|ClinicalTrials.gov Identifier: NCT00004665|
Recruitment Status : Completed
First Posted : February 25, 2000
Last Update Posted : June 24, 2005
I. Evaluate the long-term safety and tolerance of a synthetic formulation of dehydroepiandrosterone, GL701, in patients with systemic lupus erythematosus who have completed a prior GL701 protocol.
|Condition or disease||Intervention/treatment||Phase|
|Systemic Lupus Erythematosus||Drug: dehydroepiandrosterone||Phase 2|
PROTOCOL OUTLINE: Patients receive daily oral dehydroepiandrosterone for 12 months. The dose is adjusted based on disease activity and tolerance of treatment.
Patients are followed every 3 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Study Start Date :||June 1995|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004665
|Study Chair:||Rosalind Ramsey-Goldman||Northwestern University|